Duke teams set treatment priorities in new national research effort

February 24, 2014

DURHAM, N.C. - Treatment regimens often evolve without strong scientific evidence of their benefits and drawbacks, particularly in comparison to other drugs or approaches.

Now Duke Medicine is participating in a large national initiative aiming to fill in that missing information.

In separate articles published Feb. 24, 2014, in the Annals of Internal Medicine, teams led by the Duke Clinical Research Institute detailed the research priorities necessary to address gaps in knowledge about two conditions - bipolar disorder among adolescents and early breast tumors in women.

The two diverse conditions provide similar challenges for patients, doctors and health system administrators: The diagnosis is often not clear-cut, while typical treatments come with a trade-off of benefits and serious side effects.

Collaborating with clinical experts, patients, patient advocates, and other stakeholders, the two Duke-led teams worked to identify and rank the important gaps in knowledge that should be the focus of new research.

Aiming patient-focused research efforts and dollars at such clinical uncertainties is the mission of a national initiative called the Patient-Centered Outcomes Research Institute (PCORI), which was established three years ago under the Affordable Care Act. Using funds from the insurance mandate, PCORI is working to improve the quality of research, speed it into clinical practice, and assure that it answers the most pressing questions and concerns of patients.

In the case of bipolar disorder among adolescents and young adults, the Duke researchers noted that establishing this diagnosis is particularly complex, and the condition can be difficult to distinguish from other behavioral disorders, including attention deficit hyperactivity disorder. Yet the use of antipsychotic drugs for this condition has increased dramatically over the past two decades, and carries with it a high risk of weight gain, diabetes and other problems.

"This is clearly an important area of clinical uncertainty that will benefit from more research," said Matthew J. Crowley, M.D., assistant professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at Duke and lead author of the study addressing research priorities for adolescents with bipolar disorder.

Likewise with ductal carcinoma in situ - tiny breast lesions detected via mammography - considerable uncertainty has evolved over whether to treat the condition as cancer. Many of the lesions may never progress to life-threatening invasive cancer, while treatment plans call for mastectomy, lumpectomy and radiation.

"We don't have a good handle on how to distinguish between the cases that will develop into invasive cancers, and those that are harmless," said Jennifer Gierisch, Ph.D., assistant professor of medicine in the Division of General Internal Medicine at Duke and lead author of the breast cancer paper. "There is a lot of uncertainty about what a diagnosis means and how to proceed around a diagnosis. Our goal is to identify research priorities to address these questions and reduce the uncertainty for both patients and doctors."

Members of the Duke Clinical Research Institute have been key players in the PCORI initiative, led by Robert Califf, M.D., who is a co-principal investigator of PCORI's national clinical research network. The group will amass, coordinate and manage the database of medical information that researchers can use to learn how well treatments work.

PCORI has also funded research at Duke, including the work of the two teams that identified research priorities in bipolar disorder and breast cancer. PCORI has provided additional funding for other Duke Clinical Research Institute members to: "We are pleased to be able to contribute to such an important national enterprise," Califf said. "Patients deserve to know the comparative risks and benefits of treatment alternatives, and PCORI is providing the focus to provide this critical knowledge."
-end-


Duke University Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.